Frogs Against Cancer: How a Bacterium from Amphibian Guts Is Rewriting Oncology
A piece of news that sounds almost like science fiction turns out, in reality, to be a careful yet truly revolutionary work at the intersection of microbiology and oncology. In the gut of the Japanese tree frog, scientists discovered the bacterium Ewingella americana, which in experiments demonstrated the ability to selectively destroy tumors.
The mechanism appears fundamentally new. Once introduced into the body, the bacterium independently migrates, locates tumor tissue, and destroys it, while largely sparing healthy organs. In experiments on mice, a single injection led to complete tumor regression, with no relapses. Cell death occurred within three days—significantly faster than with most standard treatment protocols.
The key point is safety. According to the researchers, Ewingella americana shows no systemic toxicity and does not damage tissues outside the tumor. This fundamentally distinguishes the approach from chemotherapy and even from many forms of immunotherapy, where side effects remain a serious issue.
It is important to emphasize that this is still at an experimental stage and based on animal models. Phrases like “cures any cancer” are media simplifications. But the very fact that a living bacterium can act as a self-targeting anti-tumor agent opens an entirely new direction in medicine—next-generation bacterial oncotherapy.
Researchers are currently preparing trials in humans. If even part of the effects is confirmed clinically, we would not be talking merely about a new drug, but about a paradigm shift: from toxic tumor suppression to biologically precise, self-regulating treatment.
